Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
About this trial
This is an interventional treatment trial for Lymphoma, Non-Hodgkin focused on measuring Dendritic cells
Eligibility Criteria
Inclusion Criteria: Histologically documented, aggressive and/or intermediate grade NHL, B-cell and T-cell. In relapse after first-line conventional chemotherapy. Primary therapy should include a doxorubicin-based regimen. Patients must have disease sensitive to induction chemotherapy, radiation therapy, and/or radioimmunotherapy. Successful treatment of CNS or meningeal disease is allowed. Patients must have accessible tumor for biopsy or excision. Cumulative total doxorubicin: <500 mg/m2 Performance score 0-2 No prior pelvic RT Patients with a prior malignancy are eligible if they were treated for cure and have no evidence of active disease. Patients may not be taking immunosuppressive agents. Informed Consent; IRB approval
Sites / Locations
- University of Michigan Medical Center